HC Wainwright Has Bullish Estimate for AGIO Q3 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities research analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research note issued on Thursday, July 30th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn ($1.27) per share for the quarter, up from their previous estimate of ($1.55). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.12) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.32) EPS, FY2026 earnings at ($5.96) EPS, FY2027 earnings at ($4.78) EPS, FY2028 earnings at ($3.53) EPS and FY2029 earnings at ($1.82) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million.

AGIO has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Truist Financial reduced their price target on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Royal Bank Of Canada lifted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Citigroup upped their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. reduced their target price on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research report on Thursday, June 11th. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and an average target price of $40.88.

Agios Pharmaceuticals Stock Up 3.5%

Shares of Agios Pharmaceuticals stock opened at $31.60 on Monday. The stock’s fifty day moving average is $34.60 and its two-hundred day moving average is $30.94. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The company has a market capitalization of $1.89 billion, a PE ratio of -4.51 and a beta of 0.58.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Creative Planning raised its holdings in shares of Agios Pharmaceuticals by 2.2% in the 3rd quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 280 shares in the last quarter. Assetmark Inc. lifted its position in shares of Agios Pharmaceuticals by 37.9% in the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Agios Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after purchasing an additional 512 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Agios Pharmaceuticals by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 588 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its holdings in Agios Pharmaceuticals by 3.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 662 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.